Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400166 | 0.96 | SCN9A (0.65) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4329519 | 0.89 | SCN9A (0.51) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4327442 | 0.88 | SCN9A (0.50) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4332131 | 0.87 | SCN9A (0.49) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4491094 | 0.86 | SCN9A (0.59) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4492039 | 0.86 | SCN9A (0.57) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4324341 | 0.85 | SCN9A (0.54) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4498464 | 0.85 | SCN9A (0.56) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4331573 | 0.84 | SCN9A (0.50) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4324382 | 0.84 | SCN9A (0.57) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1694654-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2005047270-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | TRPV1, SCN3A, SCN5A | SCN9A 50/4885CYP2C9 565/4885CYP3A4 699/4885 |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | TRPV1, SCN3A, SCN5A | SCN9A 50/4885CYP2C9 574/4885CYP3A4 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.